Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

Condition:   Early Breast Cancer Interventions:   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Taxane;   Drug: Letrozole;   Drug: Abemaciclib;   Drug: LHRH Analogue Sponsors:   Spanish Breast Cancer Research Group;   Eli Lilly and Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials